Neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
- Author:
Jung Bin SOHN
1
;
Duck Yeong RO
;
Yong Wook KIM
;
Tae Eung KIM
;
Jae Keun JUNG
;
Chi Wha HAN
;
Ye Hoon CHOI
Author Information
1. Department of Obstetrics and Gynecology, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. duckyeong20@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Neoadjuvant chemotherapy (NAC);
Ovarian cancer
- MeSH:
Adenocarcinoma;
Blood Transfusion;
Carboplatin;
Drug Therapy*;
Female;
Humans;
Intensive Care Units;
Length of Stay;
Mucins;
Operative Time;
Ovarian Neoplasms*;
Paclitaxel;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Obstetrics and Gynecology
2007;50(10):1371-1377
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study was aimed at comparison of women with advanced ovarian cancer treated with neoadjuvant chemotherapy (NAC) followed by surgery with those treated conventionally with primary debulking surgery followed by cytotoxic chemotherapy (conventional group). METHODS: Between January 1998 and December 2005, 11 patients with advanced epithelial ovarian cancer were treated by NAC followed by debulking surgery and 20 patients were treated by primary cytoreductive surgery followed by cytotoxic chemotherapy conventionally. The files were reviewed retrospectively. RESULTS: The mean age was 54.8+/-11.6 in NAC and 53.0+/-11.9 years in conventional group. 10 cases were serous adenocarcinoma in NAC group and 16 cases were serous, 1 was mucinous and 2 cases were endometrioid type in conventional group (Table 1). Mean courses of NAC were 3 cycles (range 1-4) and carboplatin and paclitaxel regimen was most common (Table 2). After NAC, 2 complete responses (18.2%) were achieved, 4 patients (36.4%) achieved a partial response, and 5 (45.5%) had no response or progressive disease. At debulking surgery, no pathological complete response was noted, and residual ovarian cancer was present in all cases. The optimal surgery (residual tumor <2 cm) was obtained in 9 cases (81.8%) of NAC and 5 cases (25.0%) of conventional group (Table 3). The mean estimated blood loss was 604.54+/-178 ml (range 400-1,000 ml) in NAC group and 752.5+/-335 ml (range 400-2,000 ml) in conventional group , blood transfusion 2.2 pints (range 0-5 pints) in NAC and 4.6 pints (range 1-19 pints) in conventional group, the mean operative time was 244.54+/-108 minutes in NAC group and 251.5+/-94.5 minutes in conventional group, mean intensive care unit stay was 1.6 days (range 0-3 days) in NAC and 2.5 days (range 0-13 days) in conventional group, and mean hospital stay was 17.36+/-8.97 days (range 7-42 days) in NAC and 24.45+/-11.7 days (range 10-48 days) in conventional group respectively (Table 4). There were no significant statistical differences in two groups except hospital stay (p=0.04). There were no significant statistical differences of disease-free and overall survival in two groups (Fig 1&2). CONCLUSION: The rate of optimal debulking surgery, blood loss, operative time, disease-free and overall survival, excluding the length of hospital stay, showed no significant statistical differences in both groups. Even though we might have statistical shortage because we were able to get only limited cases to show meaningful results, there is enough validity of conducting prospective clinical research using NAC since the overall survival rate in both groups showed no significant difference.
